Achieve Life Sciences (NASDAQ:ACHV) Lifted to Buy at ValuEngine

ValuEngine upgraded shares of Achieve Life Sciences (NASDAQ:ACHV) from a hold rating to a buy rating in a research report released on Friday, ValuEngine reports.

Several other equities research analysts have also recently weighed in on the stock. Maxim Group reiterated a buy rating and set a $6.00 price objective on shares of Achieve Life Sciences in a research report on Tuesday, October 1st. LADENBURG THALM/SH SH reiterated a buy rating and set a $20.00 price objective on shares of Achieve Life Sciences in a research report on Friday, August 9th.

Shares of ACHV traded down $0.02 during trading hours on Friday, hitting $0.89. 125,502 shares of the stock were exchanged, compared to its average volume of 607,525. Achieve Life Sciences has a fifty-two week low of $0.84 and a fifty-two week high of $4.63. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.62 and a quick ratio of 3.62. The business has a 50-day moving average of $1.58 and a 200-day moving average of $2.41. The firm has a market capitalization of $9.88 million, a P/E ratio of -0.25 and a beta of 1.91.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.23). As a group, analysts forecast that Achieve Life Sciences will post -1.6 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in Achieve Life Sciences in the second quarter worth $32,000. Searle & CO. grew its holdings in Achieve Life Sciences by 80.4% in the second quarter. Searle & CO. now owns 132,592 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 59,092 shares during the period. Vanguard Group Inc. grew its holdings in Achieve Life Sciences by 152.2% in the second quarter. Vanguard Group Inc. now owns 274,519 shares of the biopharmaceutical company’s stock worth $530,000 after purchasing an additional 165,667 shares during the period. Renaissance Technologies LLC grew its holdings in Achieve Life Sciences by 12.5% in the second quarter. Renaissance Technologies LLC now owns 321,268 shares of the biopharmaceutical company’s stock worth $620,000 after purchasing an additional 35,607 shares during the period. Finally, Sio Capital Management LLC grew its holdings in Achieve Life Sciences by 24.4% in the second quarter. Sio Capital Management LLC now owns 524,413 shares of the biopharmaceutical company’s stock worth $1,012,000 after purchasing an additional 102,934 shares during the period. Institutional investors own 18.63% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

See Also: G-20

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.